Close

Registration is free and only takes a moment. If you have already registered, please log in now.

Create Account
Forgot your password?
Log In
  • Links
  • Aggregator Full Text
  • Authors
  • McBride D
  • MESH
  • Antineoplastic Agents
  • Genetic Markers
  • Humans
  • Leukemia, Myeloid, Acute
  • Mutation
  • Prognosis
  • fms-Like Tyrosine Kinase 3

Unbound MEDLINE

Mutated gene markers predict outcome for patients with AML.

Links

  • Aggregator Full Text
  • Authors

    McBride D

    Institution

    Kaiser Permanente Oakland Medical Center, CA USA.

    Source

    ONS connect 27:5 2012 May pg 21

    MeSH

    Antineoplastic Agents
    Genetic Markers
    Humans
    Leukemia, Myeloid, Acute
    Mutation
    Prognosis
    fms-Like Tyrosine Kinase 3

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    22690521

    Related Citations

    • Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
    • Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
    • FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
    • FLT3 inhibitors for the treatment of acute myeloid leukemia.
    • Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
    • Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutations.
    • Diagnosis and prognosis in acute myeloid leukemia--the art of distinction.
    • Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    More
    unbound logo
    • Home »
    • Contact Us »
    • Help »
    • Privacy / Disclaimer »
    • Terms of Service »
    • Log In »
    • twitter
    • facebook
    © 2000–2013 Unbound Medicine, Inc. All rights reserved